Executive Briefing: C-Suite And Investors Discuss A New Decade
What Will The Biopharma Industry Face In The 2020s?
• By William Masters
In Vivo held its first executive briefing in December 2019 focused on the outlook for the biopharma sector in the 2020s. Looking to the next decade, six panelists debated in front of an audience of invited guests a variety of issues expected to dominate agendas: pricing and reimbursement, digital transformation, mergers and acquisitions, funding and more.
A New Decade Has Dawned For Biopharma • Source: Shutterstock
From the US election to being over-focused on oncology, from the promise of artificial intelligence to private funding in Europe – there were a range of issues and opportunities discussed at In Vivo’s inaugural executive briefing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.
Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.
